The global GLP-1 for Weight Loss market size is predicted to grow from US$ 4713 million in 2025 to US$ 14990 million in 2031; it is expected to grow at a CAGR of 21.3% from 2025 to 2031.

GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone in the body that plays a role in glucose homeostasis and appetite regulation. In the context of weight loss, GLP-1 has gained attention due to its potential to influence body weight.

GLP-1-based medications, such as GLP-1 receptor agonists, are a class of drugs used primarily for the treatment of type 2 diabetes. However, they have also been found to have beneficial effects on body weight. These drugs mimic the action of GLP-1 in the body, leading to increased insulin secretion, decreased glucagon release, slowed gastric emptying, and a sense of fullness. These effects collectively contribute to improved blood sugar control and a reduction in appetite and food intake.

Expanding Indications: GLP-1 receptor agonists were primarily developed for the treatment of type 2 diabetes. However, there was growing interest in their potential application for weight management in individuals without diabetes. Some GLP-1 medications received regulatory approval for weight loss.

New Drug Development: Pharmaceutical companies were investing in the research and development of new GLP-1 receptor agonists with enhanced properties, including improved efficacy, longer duration of action, and better tolerability. These developments aimed to address various patient needs and preferences.

Combination Therapies: Researchers were exploring the use of GLP-1 medications in combination with other weight loss therapies, such as anti-obesity medications or lifestyle interventions. Combining different approaches could provide synergistic effects in promoting weight loss.

Increased Patient Awareness: As more research findings became available and regulatory approvals were granted for weight management, there was an increased awareness among healthcare professionals and patients regarding the potential benefits of GLP-1 receptor agonists for weight loss.

Market Competition: With the emergence of new medications and indications, the market for GLP-1-based therapies for weight loss was becoming more competitive. This competition could drive innovation and potentially lead to more accessible and diverse treatment options.

Infinity Market Research newest research report, the GLP-1 for Weight Loss Industry Forecast looks at past sales and reviews total world GLP-1 for Weight Loss sales in 2024, providing a comprehensive analysis by region and market sector of projected GLP-1 for Weight Loss sales for 2025 through 2031. With GLP-1 for Weight Loss sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 for Weight Loss industry.

This Insight Report provides a comprehensive analysis of the global GLP-1 for Weight Loss landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 for Weight Loss portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global GLP-1 for Weight Loss market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 for Weight Loss and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 for Weight Loss.

This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 for Weight Loss market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Injection
    Oral Agent

Segmentation by Application:

    Woman
    Man

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Novo Nordisk
    AstraZeneca
    Eli Lily
    GSK
    Sanofi
    Bristol-Myers Squibb
    Amylin

Key Questions Addressed in this Report

What is the 10-year outlook for the global GLP-1 for Weight Loss market?
What factors are driving GLP-1 for Weight Loss market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 for Weight Loss market opportunities vary by end market size?
How does GLP-1 for Weight Loss break out by Type, by Application?